Marshall Wace, LLP Albireo Pharma, Inc. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $3.09 Million - $4.36 Million	-129,126 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $1.9 Million - $2.81 Million	-89,833 Reduced 41.03%	129,126 $3.01 Million
Q3 2021 Nov 15, 2021	SELL	$27.36 - $35.98 $1.12 Million - $1.47 Million	-40,948 Reduced 15.75%	218,959 $6.83 Million
Q2 2021 Aug 13, 2021	SELL	$28.9 - $36.87 $6.36 Million - $8.12 Million	-220,160 Reduced 45.86%	259,907 $9.14 Million
Q1 2021 May 17, 2021	SELL	$32.03 - $42.85 $6.01 Million - $8.04 Million	-187,636 Reduced 28.1%	480,067 $16.9 Million

Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $815,257 - $1.09 Million	-25,832 Reduced 3.72%	667,703 $25 Million
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $14.1 Million - $25.3 Million	608,709 Added 717.6%	693,535 $23.1 Million
Q2 2020 Aug 13, 2020	BUY	$14.82 - $29.92 $1.26 Million - $2.54 Million	84,826 New	84,826 $2.25 Million
Q1 2020 May 15, 2020	SELL	$11.67 - $27.23 $112,673 - $262,905	-9,655 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.92 - $28.96 $131,502 - $225,077	7,772 Added 412.75%	9,655 $246,000
Q3 2019 Nov 14, 2019	BUY	$20.0 - $31.88 $37,660 - $60,030	1,883 New	1,883 $38,000
Q2 2019 Aug 14, 2019	SELL	$30.67 - $37.86 $57,751 - $71,290	-1,883 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$20.9 - $32.57 $39,354 - $61,329	1,883 New	1,883 $46,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.